Repurposing a peptide toxin from wasp venom into antiinfectives with dual antimicrobial and immunomodulatory properties

© 2020 National Academy of Sciences. All rights reserved. Novel antibiotics are urgently needed to combat multidrug-resistant pathogens. Venoms represent previously untapped sources of novel drugs. Here we repurposed mastoparan-L, the toxic active principle derived from the venom of the wasp Vespula...

Full description

Bibliographic Details
Main Authors: Silva, Osmar N, Torres, Marcelo DT, Cao, Jicong, Alves, Elaine SF, Rodrigues, Leticia V, Resende, Jarbas M, Lião, Luciano M, Porto, William F, Fensterseifer, Isabel CM, Lu, Timothy K, Franco, Octavio L, de la Fuente-Nunez, Cesar
Other Authors: Massachusetts Institute of Technology. Synthetic Biology Center
Format: Article
Language:English
Published: Proceedings of the National Academy of Sciences 2021
Online Access:https://hdl.handle.net/1721.1/134150
Description
Summary:© 2020 National Academy of Sciences. All rights reserved. Novel antibiotics are urgently needed to combat multidrug-resistant pathogens. Venoms represent previously untapped sources of novel drugs. Here we repurposed mastoparan-L, the toxic active principle derived from the venom of the wasp Vespula lewisii, into synthetic antimicrobials. We engineered within its N terminus a motif conserved among natural peptides with potent immunomodulatory and antimicrobial activities. The resulting peptide, mast-MO, adopted an α-helical structure as determined by NMR, exhibited increased antibacterial properties comparable to standard-of-care antibiotics both in vitro and in vivo, and potentiated the activity of different classes of antibiotics. Mechanism-of-action studies revealed that mast-MO targets bacteria by rapidly permeabilizing their outer membrane. In animal models, the peptide displayed direct antimicrobial activity, led to enhanced ability to attract leukocytes to the infection site, and was able to control inflammation. Permutation studies depleted the remaining toxicity of mast-MO toward human cells, yielding derivatives with antiinfective activity in animals. We demonstrate a rational design strategy for repurposing venoms into promising antimicrobials.